IP Library Granted Patent US 7,368,572
Granted Patent B2
US 7,368,572 · App. 10/922,119 · Granted May 6, 2008

Acetylene derivatives as inhibitors of histone deacetylase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,572
App. No.
10/922,119
Granted
May 6, 2008
Kind
B2
Abstract

The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Claims (63)

1. A compound of Formula (I):

wherein:

R is hydrogen;

Ar 1 is phenylenc and the triple bond attached to Ar 1 is in the para position relative to the —CONHOH group, wherein said Ar 1 is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, haloalkoxy, or haloalkyl;

X and Y are a bond;

R 1 and R 2 are hydrogen or alkyl;

Z is —CONH—;

Ar 2 is heteroaryl;

and individual stercoisomers, individual geometric isomers, or mixtures thereof: or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein Ar 2 is thiophenyl, pyridinyl, quinolinyl, thiazolyl, benzthiazolyl, benzoxazolyl, furanyl, benzimidazolyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, or isoquinolinyl optionally substituted with one or two substituents independently selected from alkyl, alkoxy, alkoxyalkyl, halo, haloalkyl, haloalkoxy, alkylamino, dialkylamino, hydroxy, hydroxyalkyl, hydroxyalkyloxy, aminoalkyl, aminoalkoxy, alkoxyalkyloxy, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted phenyloxyalkyl, optionally substituted heteroaralkyloxy, optionally substituted heteroaryloxyalkyl, optionally substituted heterocycloalkylalkyloxy, or optionally substituted heterocycloalkylalkyl.

3. The compound of claim 1 wherein Ar 2 is thiazolyl, quinolinyl, oxazulyl, benzothiophenyl, indolyl, benzofuranyl, benzthiazolyl, or benzimidazolyl optionally substituted with a substituent selected from halo, haloalkyl, alkoxy, haloalkoxyalkyl, aminoalkoxy, aminoalkyl, alkoxyalkyloxy, alkoxyalkyloxyalkyl, optionally substituted heterocycloalkyloxy, optionally substituted hetrocycloalkylalkyloxy, or phenyl optionally substituted with -(alkylene)NRR′ where R and R′ are independenly hydrogen or alkyl.

4. A compound selected from the group consisting of;

N-hydroxy-4-[3-(3-phenylacryloylamino)prop-1-ynyl]-benzamide,

N-hydroxy-4-[3-(4-phenylthiazol-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-S-(3-phenylacryloylamino)-but-1-ynyl]-benzamide;

N-hydroxy-4-[3-(4-methoxyquinolin-2-ylcarbonylamino)prop-ynyl]-benzamide;

N-hydroxy-4-{3-[2-(4-aminomethylphenyl)oxazol-5-ylcarbonylamino}prop-1-ynyl]-benzamide hydrochloride;

N-hydroxy-4-[3S-(4-phenylthiazol-2-ylcarbonylamino)but-1-ynyl]-benzamide;

N-hydroxy-4-[3-(phenylcarbonlamino)prop-1-ynyl[-benzamide;

N-hydroxy-4-[3-(benzothiophen-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(5-chlorobenzofuran-2-ylcarbonylamino)-prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(5-indol-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(benzofuran-2-ylcarbonylamino)prop-1-ynyl]-benzarmide;

N-hydroxy-4-[3S-(benzothiophen-2-ylcarbonylamino)but-1-ynyl]-benzamide;

N-hydroxy-4-[3-(indol-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-{3-[3-(2,2,2-trifluoroethyloxymethyl)benzofuran-2-yl-carbonyl-amino]prop-1-vnyl }-benzamide;

N-hydroxy-4-[3-(benzthiazol-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(4-trifluorornethylbenzothiophen-2-ylcarbonyl-amino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(5-fluorobenzothiophen-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(3-N,N-dimethylaminomethylbenzofuran-2-ylcarbonylamino)prop-1-ynyl]-benzamide hydrochloride;

N-hydroxy-4-{3-[1-(2-N,N-dimethylaminoethyl)benzimidazol-2-ylcarbonyl-amino]prop-1-ynyl}benzamide;

N-hydroxy-4-[3-(4-methoxybenzofuran-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(4-N,N-dimethylaminoethoxybenzofuran-2-ylcazbonylamino-)prop-1-ynyl]-benzamide hydrochloride,

N-hydroxy-4-[3-(4-methoxyindol-2ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(4-N,N-dimethylaminoethoxyindol-2-yl-carbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(5-methoxyindol-2-ylcarbonylamino)prop-1-ynyl]-benzamide;

N-hydroxy-4-[3-(5-N,N-dimethylaminoethoxyindol-2-ylcarbonyl-amino)prop-1-ynyl]-benzamide hydrochloride;

N-hydroxy-4-{3-[3-(2-methoxyethyloxymethyl)-benzofuran-2-yl-carbonylamino]prop-1-ynyl]benzamide;

N-hydroxy-4-{3-[3-(2-methoxyethyloxy)indol-2-yl-carbonylamino]prop-1-ynyl}-benzamide;

N-hydroxy-4-[3-(5-tetrahydropyran-4-yloxybenzofuran-2-yl-carbonylamino)prop-1-ynyl]benzamide;

N-hydroxy-4-{3-[5-(2-pyrrolidin-1-ylethoxy)benzofuran-2-yl-carbonylamino]prop-1-ynyl}benzamide hydrochloride;

N-hydroxy-4-{3-[5-(2-methoxyethyloxy)benzofuran-2-yl-carbonylamino]prop-1-ynyl}-benzamide;

N-hydroxy-4-{3-[4-(N,N-dimethylaminoethyloxy)quinolin-2-yl-carbonylamino]prop-1-ynyl}benzamide hydrochloride;

N-hydroxy-4-{3-[5-(1-(2,2,2-trifluoroethyl)piperidin-4-yloxy)benzofuran-2-ylcarbonyl-amino ]prop-1-ynyl}benzamide;

N-hydroxy-4-{3-[5-(1-cyclopropylpiperidin-4-yloxy)benzofuran-2-yl-carbonylamino]-prop-1-ynyl}benzamide hydrochloride;

N-hydroxy-4-{3-[5-(tetrahydropyran-4-ylmethyloxy)benzofuran-2-ylcarbonylamino]-prop-1-ynyl}benzamide;

N-hydroxy-4-{3-[5-(2-morpholin-4-ylethyloxy)benzofuran-2-yl-carbonylamino]prop-1-ynyl}benzamide hydrochloride;

N-hydroxy-4-{3-[3-(4-chlorophenyl)ureido]prop-1-ynyl}benzamide;

N-hydroxy-4-{3-[3-(4-trifluorormethylphenyl)ureido]prop-1-ynyl}benzamide;

N-hydroxy-4-{3-[3-(phenyl)ureido]prop-1-ynyl}benzamide;

N-hydroxy-4-{3-[3-(2-trifluoromethyloxyphenyl)ureido]prop-1-ynyl}benzamide;

N-hydroxy-4-[3-methyl-3-(3-phenylacryloylamino)but-1-ynyl]-benzamide;

N-hydroxy-4-[3-methyl-3-(4-phenylthiazol-2-ylcarbonylamino)but-1-ynyl]-benzamide;

N-hydroxy-4-[3-methyl-3-(benzithiazol-2-ylcarbonylamino)but-1-ynyl]-benzamide; and

N-hydroxy-4-[3-methyl-3-(benzofuran-2-ylcarbonylamino)but-1-ynyl]-benzamide; or a pharmaceutically acceptable salt thereof.

5. N-hydroxy-4-[3-(5-N,N-dimethylaminoethoxyindol-2-ylcarbonylamino)prop-1-ynyl}-benzamide; or a pharmaceutically acceptable salt thereof and having the structure:

6. N-hydroxy-4-[3-(2-methoxyethyloxymethyl)indol-2-ylcarbonylamino)prop-1-ynyl]-benzamide; or a pharmaceutically acceptable salt thereof and having the structure:

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable excipient.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 3 and a pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 4 and a pharmaceutically acceptable excipient.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 5 and a pharmaceutically acceptable excipient.

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 6 and a pharmaceutically acceptable excipient.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0377. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038722/0776 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0398. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded May 17, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038722/0849 →
MERGER Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0377 →
MERGER AND CHANGE OF NAME Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2006
From: AXYS PHARMACEUTICALS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 018378/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2005
From: SENDZIK, MARTIN
To: AXYS PHARMACEUTICALS, INC
Reel/Frame 015968/0094 →